BLUE News and Press, bluebird bio Inc. From 06/09/22

Bluebird bio (NASDAQ:BLUE) said Nasdaq has halted trading of its common shares for June 9-10, ahead of a U.S. Food and Drug Administration (FDA) panel meeting to discuss applications seeking approval of its gene therapies. Earlier in the week, the company's shares gained after the FDA re...

- BLAs for beti-cel for beta-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced t...

A group of biotechs focused on gene therapy candidates surged on Tuesday after the FDA posted a favorable review on a β-thalassemia candidate developed by commercial-stage company Bluebird bio (NASDAQ:BLUE) ahead of an AdCom meeting later this week. The data for the marketing applicati...

Update: Bluebird bio (NASDAQ:BLUE) shares gained after the FDA reviewers issued favorable remarks on the company’s gene therapy candidate for β-thalassemia, beti-cel. Commenting on its efficacy, the FDA staff wrote that the data in its marketing application “support the e...

Bluebird bio (NASDAQ:BLUE), a commercial-stage biotech focused on genetic diseases, announced on Tuesday that the FDA posted briefing documents as a group of its outside experts plans to meet this week to review two of the company’s gene therapies. Bluebird (BLUE) shares traded lower a...

June 9 discussion will focus on eli-cel for the treatment of early active cerebral adrenoleukodystrophy in patients without a matched sibling donor and overall safety of lentiviral vector (LVV) gene therapy June 10 discussion will focus on beti-cel for the treatment of β...

FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma (INO), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), Ocu...

Tang Capital Partners has disclosed a 5.2% stake in bluebird bio (NASDAQ:BLUE), according to an SEC filing. The investment firm owns 3,721,056 shares. Based on Friday's closing price, its stake is worth ~$11.8M. Although beaten down, see why Seeking Alpha contributor Terry Chrisomalis says bl...

Bluebird Bio (BLUE), Clovis Oncology (NASDAQ:CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out of cash within the next six months. The analysis of 118 companies developing cancer medications exclu...

Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in May from 20 previously. Adding market capitalization to total debt and deducting cash and cash equivalents, ...